Recombinant Human CEACAM-5/CD66e Protein, CF

Recombinant Human CEACAM-5/CD66e (Catalog # 4128-CM) has a molecular weight (MW) of 203.6 kDa as analyzed by SEC-MALS, suggesting that this protein is a homodimer. MW may differ from predicted MW due to post-translational modifications (PTMs) present (i.e. Glycosylation).

• Reactivity: Hu
• Applications: Binding Activity
• Format: Carrier-Free

Recombinant Human CEACAM-5/CD66e Protein, CF Summary

• Additional Information: Analyzed by SEC-MALS, His-tag
• Details of Functionality: Measured by its binding activity in a functional ELISA. Ideo, H. et al. (2005) J. Biol. Chem. 280:4730. Recombinant Human CEACAM-5/CD66e can bind Recombinant Human Galectin‑4 (Catalog # 1227-GA with an estimated K_d <4 nM.
• Source: Mouse myeloma cell line, NS0-derived human CEACAM-5/CD66e protein
  Lys35-Ala685, with a C-terminal 6-His tag
• Accession #: Q8N4D0
• N-terminal Sequence: Lys35
• Protein/Peptide Type: Recombinant Proteins
• Gene: CEACAM5
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.01 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Binding Activity
• Theoretical MW: 72 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 155-180 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human CEACAM-5/CD66e Protein, CF

• Carcinoembryonic antigen
• carcinoembryonic antigen-related cell adhesion molecule 5
• CD66e antigen
• CD66e
• CEA
• CEACAM5
• CEACAM-5
• CEACD66e
• DKFZp781M2392
• Meconium antigen 100

Background

CEACAM-5, also known as CEA and CD66e, belongs to the large family of CEACAM and pregnancy specific glycoproteins. CEACAM molecules are either transmembrane or GPI-linked, and are differentially expressed between species (1, 2). Orthologs of human CEACAM-5 have not been described in other species. CEACAM-5, which is expressed primarily by epithelial cells, consists of an N-terminal Ig-like V-set domain followed by six Ig-like C2-set domains and a GPI anchor
(2-4). CEACAM-5 is synthesized as a 180 kDa, variably glycosylated molecule of which approximately 60% is carbohydrate (5). CEACAM-5 functions as a
calcium-independent adhesion molecule through homophilic and heterophilic interactions with CEACAM-1 (6-8). CEACAM-5 is restricted to the apical face of intestinal epithelial cells in the adult but is more diffuse during embryonic development and in tumors (7). This is consistent with a role in the development and maintenance of epithelial architecture. CEACAM-5 is up-regulated in a wide variety of human tumors and is a commonly used cancer marker (9). It promotes tumor cell migration, invasion, adhesion, and metastasis (10). It also contributes to tumor formation by maintaining cellular proliferation in the presence of differentiation stimuli, and by blocking apoptosis following loss of ECM anchorage (anoikis) (11, 12). The GPI anchoring of CEACAM-5 can be released by GPI-PLD, resulting in a soluble molecule that also promotes tumor metastasis (13). Cell surface expression of CEACAM-5 on tumor cells prevents the adhesion of CEACAM-1 expressing NK cells and provides protection from NK-mediated lysis (6). CEACAM-5 also binds a subset of Neisseria opacity proteins (Opa) and E. coli adhesion proteins (14-16). These interactions trigger clustering of the lipid raft-localized CEACAM-5 to sites of pathogen contact (15, 16).

1. Zebhauser, R. et al. (2005) Genomics 86:566.
2. Hammarstrom, S. (1999) Semin. Cancer Biol. 9:67.
3. Schrewe H. et al. (1990) Mol. Cell. Biol. 10:2738.
4. Hefta, S.A. et al. (1988) Proc. Natl. Acad. Sci. 85:4648.
5. Garcia, M. et al. (1991) Cancer Res. 51:5679.
6. Stern, N. et al. (2005) J. Immunol. 174:6692.
7. Benchimol, S. et al. (1989) Cell 57:327.
8. Zhou, H. et al. (1993) J. Cell Biol. 122:951.
9. Goldenberg, D.M. et al. (1976) J. Natl. Cancer Inst. 57:11.
10. Blumenthal, R.D. et al. (2005) Cancer Res. 65:8809.
11. Screaton, R.A. et al. (1997) J. Cell Biol. 137:939.
12. Ordonez, C. et al. (2000) Cancer Res. 60:3419.
13. Yamamoto, Y. et al. (2005) Biochem. Biophys. Res. Commun. 333:223.
14. Chen, T. et al. (1997) J. Exp. Med. 185:1557.
15. Bos, M.P. et al. (1997) Infect. Immun. 65:2353.
16. Berger, C.N. et al. (2004) Mol. Microbiol. 52:963.

Publications for CEACAM5/CD66e (4128-CM)(1)

Publication using 4128-CM

• M Yarchoan, CY Huang, Q Zhu, AK Ferguson, JN Durham, RA Anders, ED Thompson, NS Rozich, DL Thomas, JM Nauroth, C Rodriguez, A Osipov, A De Jesus-A, DT Le, AG Murphy, D Laheru, RC Donehower, EM Jaffee, L Zheng, NS Azad A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer Cancer Med, 2019-12-26;0(0):. 2019-12-26 [PMID: 31876399] (ELISA Capture, Human)

Bioinformatics

• Gene Symbol: CEACAM5
• Uniprot:
  • Q8N4D0()